ASC22 Combined With Peg-IFNa in Achieving Functional Cure in Patients With Chronic Hepatitis B Virus Infection

NCT07573943 · clinicaltrials.gov ↗

PHASE4

Phase

RECRUITING

Status

150

Enrollment

OTHER

Sponsor class

Conditions

Chronic Hepatitis b

Interventions

DRUG: Anti-PD-L1 antibody (ASC22)
DRUG: Nucleotide analogs
DRUG: Peg-IFNα

Sponsor

The Second Affiliated Hospital of Chongqing Medical University

Collaborators

[object Object]
[object Object]
[object Object]